H.C. Wainwright Reiterates Buy Rating, $7 Price Target on VYNE Therapeutics (VYNE) May 18, 2022 06:08AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion" May 13, 2022 06:27AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis" Apr 7, 2022 09:08AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated Mar 17, 2022 10:55AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight, Newest Data Supports Positive Thesis for Stock Mar 7, 2022 07:36AM


Jan 13, 2022 08:12AM VYNE Therapeutics (VYNE) MST Sale is Good news, Underscores Company's Ability to Execute - Cantor Fitzgerald